Literature DB >> 3377467

In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.

H C Neu1, A Novelli, G Saha, N X Chin.   

Abstract

The antibacterial activities of DuP 105 and DuP 721, new oxazolidinone antimicrobial agents, were compared with those of beta-lactams and glycopeptides. Ninety percent of Staphylococcus aureus and Staphylococcus epidermidis isolates, including methicillin-resistant isolates, were inhibited by 4 micrograms of DuP 105 and 1 microgram of DuP 721 per ml. DuP 721 inhibited hemolytic streptococcus groups A, B, C, F, and G at a concentration of less than or equal to 1 microgram/ml, and it inhibited viridans group streptococci at a concentration of 2 micrograms/ml. Both agents inhibited Listeria monocytogenes, Corynebacterium group JK species, anaerobic cocci, and Clostridium spp. including Clostridium difficile. They did not inhibit members of the family Enterobacteriaceae or Pseudomonas aeruginosa, but the MIC for 90% of Bacteroides fragilis isolates was 8 micrograms of DuP 721 per ml.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377467      PMCID: PMC172224          DOI: 10.1128/AAC.32.4.580

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

Review 1.  Staphylococcus epidermidis infections.

Authors:  F D Lowy; S M Hammer
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

2.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

3.  The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit.

Authors:  R W Haley; A W Hightower; R F Khabbaz; C Thornsberry; W J Martone; J R Allen; J M Hughes
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

4.  Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.

Authors:  A M Slee; M A Wuonola; R J McRipley; I Zajac; M J Zawada; P T Bartholomew; W A Gregory; M Forbes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

  4 in total
  11 in total

1.  Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.

Authors:  E Mini; A Novelli; T Mazzei; P Periti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

2.  In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.

Authors:  Eun Jeong Yoon; Yeong Woo Jo; Sung Hak Choi; Tae Ho Lee; Jae Keol Rhee; Moohi Yoo; Mi Ja Shim; Eung Chil Choi
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

Authors:  C W Ford; J C Hamel; D M Wilson; J K Moerman; D Stapert; R J Yancey; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Clinical experience with linezolid in the treatment of resistant gram-positive infections.

Authors:  S J Antony; E Diaz-Vasquez; C Stratton
Journal:  J Natl Med Assoc       Date:  2001-10       Impact factor: 1.798

5.  Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.

Authors:  M J Rybak; D M Cappelletty; T Moldovan; J R Aeschlimann; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 6.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

7.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

Authors:  G G Zhanel; C Shroeder; L Vercaigne; A S Gin; J Embil; D J Hoban
Journal:  Can J Infect Dis       Date:  2001-11

9.  In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Syntheses and biological studies of novel spiropiperazinyl oxazolidinone antibacterial agents using a spirocyclic diene derived acylnitroso Diels-Alder reaction.

Authors:  Cheng Ji; Weimin Lin; Garrett C Moraski; Jane A Thanassi; Michael J Pucci; Scott G Franzblau; Ute Möllmann; Marvin J Miller
Journal:  Bioorg Med Chem       Date:  2012-04-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.